Diabetes Mellitus Screening (2024)

Definition/Introduction

Screening for any disease is fruitful when there is benefit from its early diagnosis and intervention. This activity discusses the screening for diabetes mellitus, which is1 of those diseases that affect millions worldwide. Diabetes Mellitus includes3 groups of diseases: type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes

Type 1 Diabetes

Type I diabetes is diagnosed after hyperglycemia symptoms like polyuria, polydipsia, weight loss, and lethargy. It can also present as diabetic ketoacidosis in resource-constrained areas. Screening for type I diabetes is still in its infancy, although trials with tests for insulin, zinc transporter 8, antibodies to islet cells, IA-2, and GAD65 are underway.[1][2]

Type 2 Diabetes

Type 2 diabetes may initially have few symptoms; however, long-term effects lead to a myriad of different problems late in the course of the disease, leading to debilitating sequelae. More than 30 million people in the US have diabetes.[3]Due to an initial silent course, it often remains undetected for quite a long time before the appearance of symptoms. The screening for the disease aims at prevention and early treatment with theassumption that there is a long-term benefit to its identification early in the disease process. The long-term benefit of screening vs. clinically detected diabetes is being explored.[4]Several studies withweak evidence suggest the merits of screening tests.[5]Screening fortype 2 diabetes canbe done by fasting blood sugar, hemoglobin (A1C), glucose tolerance testing, and random plasma sugar. Urine glucose may be useful, but it is an inferior test to screen for diabetes, although research is reconsidering this claim.[6]

The screening is said to be positive if there are2 abnormal tests from the same sample or2 separate samples for the first3 tests below:[7]

HbA1C over 6.5 percent[8]
Fasting plasma glucose greater than or equal to 126 mg/dL
2-hour glucose greater than or equal to 200 mg/dL in an oral glucose tolerance test with 75 mg glucose load.
Random blood glucose greater than or equal to 200 mg/dL in symptomatic patients (thirst, polyuria, weight loss, blurry vision)

For the diagnosis of diabetes mellitus, symptomatic patients require no further tests. HbA1C values can be affected by factors that increase or decrease the RBC lifespan. Anemic states falsely increase HbA1C values, whereas their treatment falsely decreases it.[9] Kidney disease can affect the values and may increase or decrease values based on the treatment the patient is getting.Erythropoietin can falsely lower HbA1c values. Hemoglobin variants like HbS and HbC also cause variations in HbA1c values.[10]The US Preventive Services Task Force's recommendation is toscreenfor diabetes between40 and 70 years who are overweight or obeseand repeat testing every3 years if results are normal.

Risk factors for diabetes include:

Hypertension
HDL < 35 mg/dL or TG > 250 mg/dL
First-degree relative with diabetes
See Also
Health Checks for People with Diabetes Diabetes Mellitus: Screening and Diagnosis Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial Screening for Type 2 Diabetes in a High-Risk Population: Effects of a Negative Screening Test After 4 Years Follow-up
High-risk race/ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
Asian Americans with a BMI of greater than or equal to 23 kg/m
Women who have delivered a child greater than 9 lbs (4 kg) or with gestational diabetes
HbA1c = 5.7%, impaired fasting glucose or impaired glucose tolerance

Other: acanthosis nigricans, polycystic ovary syndrome, history of coronary vascular disease, physical inactivity[11][7]The recommendations for those with a high risk of developing diabetes are candidates for more early/frequent screening, early behavior intervention, and intensive treatment. The recommended interval for the screening of asymptomatic patients is3 years. The interval can be short in patients who have obesity and other major risk factors for developing diabetes. The American Diabetes Association recommends screening for diabetes in adults aged 45 years or older and screening in persons with multiple risk factors regardless of age. The American Association of Clinical Endocrinologists, American Academy of Family Physicians, Diabetes Australia,Diabetes UK,and the Canadian Task Force on Preventive Health Care have recommendations that differ in their approach to screening but acknowledge and stress risk factors compared to an older age.

Gestational Diabetes

Gestational diabetes adversely impacts the lives of both fetus and mother, making screening for it an essential part of obstetric care. Screening is necessary for 1 of the risk factors for diabetes. In addition to the risk factors discussed above, others include:

History of prediabetes (impaired glucose tolerance/fasting glucose, HbA1C>5.7)
Prior history of gestational diabetes
BMI>30 kg/m²
Family history of diabetes
Multiple gestations
Old maternal age
Glycosuria at the first prenatal visit
History of unexplained miscarriage or malformation

In the US, all women are screened for gestational diabetes, as most of them have at leasta few of these risk factors. HbA1C and fasting blood glucose have not been found useful for screening gestational diabetes. A glucose tolerance test is helpful in effective screening for this condition.[12]Two ways are screening for gestational diabetes can be done:

One-step method: Glucose tolerance test with 75 mg glucose load (overnight fast required).
Two-step method: First, a 50 g glucose challenge test, which, if positive, is followed by a confirmatory second 3-hour glucose tolerance test with a 100 g glucose load.

The 1-step 75 g glucose tolerance test is simpler and widely used. The test is positive if it satisfies any1 of the following: fasting glucose≥92 mg/dL (5.1 mmol/L),1hr glucose≥180 mg/dL (10.0 mmol/L), or 2hr glucose≥153 mg/dL(8.5 mmol/mol)

Issues of Concern

There are many ongoing attempts to predict type 1 diabetes mellitus; all are still in the research phases. The level of evidence regarding the usefulness of screening for type 2 diabetes for long-term complications, especially macrovascular complications, has been a matter of debate. There are conflicting studies that show no mortality benefit of screening for diabetes compared to those who receive a diagnosis on a clinical basis. Newer studies dispute this claim as more data for greater than10 years becomes available in the future.[5]Although the screening may lead to an increase in patients receiving overtreatment and give rise to issues like polypharmacy, side effects, increased cost, etc, experts believe the benefit achieved from the treatment of this disorder to be far higher.[4][13]The recommendations are, at present, based upon the different sets of risk factors to determine those who are considered moderate or high risk. Each such recommendation defines high-risk patients differently. As more data emerges, theremaybe more congruency in those definitions. Among the different methods to determine the level of risk of developing diabetes,1 of the most popular is FINDRISC.[14] Further improvement in such scoring systems could lead to a better selection of patients who undergo screening, leading to improved care at scale. Such methods can bring uniformity in the screening process for diabetes.

Clinical Significance

There is compelling evidencethat early treatment of diabetes can reduce microvascular complications of diabetes.[15]The prompt treatment of the disease has significantly improved mortality, especially related tovascular disease.[5]The evidence for the impact of screening for diabetes is increasing. It is considered to be1 of the more straightforward ways to prevent and reduce morbidity and mortality of this disease. Excess mortality related to type 2 diabetes results from cardiovascular events, and early screening has the potential to allow for early intervention. The UKPDS demonstrated a 14% reduction inmyocardial infarctions for every 1% decrease in HbA1c value.[16]Gestational diabetes is an identified cause of several adverse outcomes during pregnancy, like pre-eclampsia, macrosomia, birth trauma, perinatal mortality, and neonatal cardiac, respiratory, and metabolic complications.[17] There is also a long-term risk of developing type 1/type 2 diabetes mellitus and cardiovascular disease in the mother, as well as metabolic syndrome, obesity, hypertension, and impaired glucose tolerance in the child. Identifying this early and prompt management has a positive impact on the health of the mother as well as the child.[18]

Nursing, Allied Health, and Interprofessional Team Interventions

The screening process invariably involves nursingpersonnel who usuallyobtain finger stick readings and perform the blood draw. Nurse practitioners and certified diabetes educators play a crucial role in education, medication reconciliation, and demonstrating theproper use of devices and medication. Their active involvement assists the medical team in recognizing the cases that could benefit from screening and assists with early detection.[19]Ahematologist and the nephrologistmay consult on the validity of a result where multiple factors could affect the test results. For example, a person with anemia or kidney disease could have altered HbA1C values. The endocrinologistmay assist and identify a group of patients who potentially have a higher risk of diabetes and recommend early/more frequent screening, such as those with other autoimmune diseases such as thyroid disease.[20]Complex cases such as those with cystic fibrosis, HIV, and post-transplant patients can be discussed with an endocrinologist to decide the usefulness of screening in such patients to form an individualized management plan. Hence, a team effort could improve screening outcomes and prevent the diagnosis from going undetected.

References

1.: Garcia-Contreras M, Brooks RW, Boccuzzi L, Robbins PD, Ricordi C. Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2017 Jun;21(12):2940-2956. [PubMed: 28682421]
2.: van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011 Jan;91(1):79-118. [PubMed: 21248163]
3.: Cannon A, Handelsman Y, Heile M, Shannon M. Burden of Illness in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S5-S13. [PMC free article: PMC10408423] [PubMed: 30156443]
4.: Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1741-8. [PMC free article: PMC3607818] [PubMed: 23040422]
5.: Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, Imperatore G. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018 Jun 16;391(10138):2430-2440. [PubMed: 29784146]
6.: Chen J, Guo H, Yuan S, Qu C, Mao T, Qiu S, Li W, Wang X, Cai M, Sun H, Wang B, Li X, Sun Z. Efficacy of urinary glucose for diabetes screening: a reconsideration. Acta Diabetol. 2019 Jan;56(1):45-53. [PubMed: 30159749]
7.: Introduction: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S1-S2. [PubMed: 31862741]
8.: Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. World Health Organization; Geneva: 2011. [PubMed: 26158184]
9.: Tarim O, Küçükerdoğan A, Günay U, Eralp O, Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int. 1999 Aug;41(4):357-62. [PubMed: 10453183]
10.: Mongia SK, Little RR, Rohlfing CL, Hanson S, Roberts RF, Owen WE, D'Costa MA, Reyes CA, Luzzi VI, Roberts WL. Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays. Am J Clin Pathol. 2008 Jul;130(1):136-40. [PubMed: 18550483]
11.: Abid A, Ahmad S, Waheed A. Screening for Type II Diabetes Mellitus in the United States: The Present and the Future. Clin Med Insights Endocrinol Diabetes. 2016;9:19-22. [PMC free article: PMC4907337] [PubMed: 27330335]
12.: Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Aktary WM, Pasichnyk D, Seida JC, Donovan L. Screening and diagnosing gestational diabetes mellitus. Evid Rep Technol Assess (Full Rep). 2012 Oct;(210):1-327. [PMC free article: PMC4781607] [PubMed: 24423035]
13.: Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019 Nov 05;367:l5887. [PubMed: 31690574]
14.: Tuomilehto J. Prevention of type 2 diabetes - where is the evidence? East Mediterr Health J. 2014 Dec 17;20(11):677-8. [PubMed: 25601804]
15.: Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. 2017 Jan 17;356:i6505. [PubMed: 28096078]
16.: Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ. 2006 Sep 02;333(7566):475-80. [PMC free article: PMC1557968] [PubMed: 16946335]
17.: Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus. Int J Mol Sci. 2018 Oct 26;19(11) [PMC free article: PMC6274679] [PubMed: 30373146]
18.: Mack LR, Tomich PG. Gestational Diabetes: Diagnosis, Classification, and Clinical Care. Obstet Gynecol Clin North Am. 2017 Jun;44(2):207-217. [PubMed: 28499531]
19.: Siminerio LM, Funnell MM, Peyrot M, Rubin RR. US nurses' perceptions of their role in diabetes care: results of the cross-national Diabetes Attitudes Wishes and Needs (DAWN) study. Diabetes Educ. 2007 Jan-Feb;33(1):152-62. [PubMed: 17272801]
20.: Wu P. Thyroid disorders and diabetes. It is common for a person to be affected by both thyroid disease and diabetes. Diabetes Self Manag. 2007 Sep-Oct;24(5):80-2, 85-7. [PubMed: 18046820]